乾性 AMD 患者を対象とした QA102 第 II 相試験 (AMEND)
乾性加齢黄斑変性症(AMD)の被験者におけるQA102の安全性と有効性を評価する第2相、ダブルマスク、無作為化、プラセボ対照、用量反応研究
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
調査の概要
詳細な説明
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85021
- Associated Retina Consultants
-
-
California
-
Mountain View、California、アメリカ、94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena、California、アメリカ、91107
- California Eye Specialists Medical Group
-
Redlands、California、アメリカ、91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach、Florida、アメリカ、33064
- Advanced Research
-
Fort Myers、Florida、アメリカ、33912
- National Ophthalmic Research Institute
-
Miami、Florida、アメリカ、33143
- MedEye Associates
-
Pensacola、Florida、アメリカ、32503
- Retina Specialty Institute
-
Pinellas Park、Florida、アメリカ、33782
- Eye Associates of Pinellas
-
Sarasota、Florida、アメリカ、34239
- Sarasota Retina Institute
-
Winter Haven、Florida、アメリカ、33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta、Georgia、アメリカ、30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest、Illinois、アメリカ、60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe、Louisiana、アメリカ、71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21209
- The Retina Care Center
-
Hagerstown、Maryland、アメリカ、21740
- Cumberland Valley Retina Consultants
-
Hagerstown、Maryland、アメリカ、21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester、Massachusetts、アメリカ、01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis、Missouri、アメリカ、63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene、Oregon、アメリカ、97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie、Pennsylvania、アメリカ、16507
- Erie Retina Research
-
-
Texas
-
Abilene、Texas、アメリカ、79606
- Retina Research Institute of Texas
-
Austin、Texas、アメリカ、78705
- Austin Research Center for Retina
-
Dallas、Texas、アメリカ、75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano、Texas、アメリカ、75075
- Texas Retina Associates - Plano
-
San Antonio、Texas、アメリカ、78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84107
- Rocky Mountain Retina Consultants
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
実験的:QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
プラセボコンパレーター:Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
時間枠:Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean Rate of GA Growth
時間枠:Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- QA102-CS201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。